Results
Concord Drugs FY26 Revenue Surges 105% to ₹758 Crore
Board approved audited standalone and consolidated financial results for Q4 and year ended 31 March 2026.
Standalone revenue surged 105% YoY to ₹758.4 crore with net profit of ₹10.4 crore (EPS: ₹0.93)
